Monday, December 23, 2024
HomeTagsDoR

DoR

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial

ImmunityBio, Inc, a clinical-stage immunotherapy company, announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics